Figure 1.
Survival according to BSA and doxorubicin dose adaptation in patients with DLBCL. PFS (A) and OS (B) according to BSA and doxorubicin dose adaptation in patients with DLBCL (Log-rank, P = .481 and P = .864, respectively). CL, confidence limits.